CLINICAL TRIALS PROFILE FOR TRIFERIC

All Clinical Trials for Triferic

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02595437 ↗	Triferic Pediatric Pharmacokinetic Protocol	Completed	Rockwell Medical Technologies, Inc.	Phase 1/Phase 2	2015-11-01	The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, two-period sequential dosing study.
NCT02636049 ↗	Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers	Completed	Rockwell Medical Technologies, Inc.	Phase 1	2015-10-01	This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
NCT02739100 ↗	Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients	Completed	Rockwell Medical Technologies, Inc.	Phase 1	2016-04-01	The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered via hemodialysate and via two different intravenous routes in adult patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, randomized single dose study.
NCT02767128 ↗	Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers	Completed	Rockwell Medical Technologies, Inc.	Phase 1	2016-04-01	The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered orally in healthy adult volunteers. It is a randomized multiple treatments, single dose study.
NCT02905981 ↗	Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol	Terminated	Rockwell Medical Technologies, Inc.	Phase 2	2017-01-17	The main purpose is to determine whether Triferic, administered orally with Shohl's solution, is safe and effective for the treatment of iron-refractory iron-deficiency anemia (IRIDA).
NCT02909153 ↗	Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis	Completed	Rockwell Medical Technologies, Inc.	Phase 1	2017-01-01	The main purpose is to determine the pharmacokinetic (PK) profile, maximum concentration (Cmax) and Area Under the Concentration Time Curve (AUC0-t) of Triferic iron administered intraperitoneally in patients with chronic kidney disease on peritoneal dialysis (CKD-5 PD). It is an open label, dose escalation study.

Clinical Trial Conditions for Triferic

Condition Name

Condition Name for Triferic
Intervention	Trials
End Stage Renal Disease	8
Iron-refractory, Iron-deficiency Anemia (IRIDA)	1
Peritoneal Dialysis (PD)	1
Anemia	1

Condition MeSH

Condition MeSH for Triferic
Intervention	Trials
Kidney Failure, Chronic	8
Kidney Diseases	2
Anemia, Iron-Deficiency	2
Renal Insufficiency, Chronic	1

Clinical Trial Locations for Triferic

Trials by Country

Trials by Country for Triferic
Location	Trials
United States	22
Puerto Rico	1

Trials by US State

Trials by US State for Triferic
Location	Trials
Florida	5
Texas	3
Michigan	2
Ohio	2
Missouri	2

Clinical Trial Progress for Triferic

Clinical Trial Phase

Clinical Trial Phase for Triferic
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Triferic
Clinical Trial Phase	Trials
Completed	9
Recruiting	1
Terminated	1

Clinical Trial Sponsors for Triferic

Sponsor Name

Sponsor Name for Triferic
Sponsor	Trials
Rockwell Medical Technologies, Inc.	11

Sponsor Type

Sponsor Type for Triferic
Sponsor	Trials
Industry	11